Light on COVID-19

Authors
Category Primary study
Registry of TrialsBrazilian Registry of Clinical Trials
Year 2020
INTERVENTION: D010789 D010814 Device Radiation Volunteers will be divided into 2 groups, composed of 20 patients each group, distributed at random, as appropriate. The sets will be formed by patients with SARS‐Cov‐2, treated with infrared LED (940 nm, optical power of 6 W, arranged in a network type distribution with a distance between them of 2 cm, energy density 1.9J / cm2) positioned in the anterior region of the chest using a vest, in an area of 64x30 cm, with application of 10 min, twice a day depending on the clinical condition of the patient, for 7 visits, and conventional treatment with antibiotic therapy associated with ventilatory monitoring of the patient. Respiratory physiotherapy will be performed before using the LED vest, for 7 sessions, lasting 30 min each session. The control group will use the LED vest in the infrared range in the off condition. As infrared radiation is not perceived by the human eye, the placebo effect will be exerted only by the vest's vest on the patient for the same time of 10 minutes, twice a day. CONDITION: B34.2 Virus diseases, of unspecified location; Coronavirus infection of unspecified location PRIMARY OUTCOME: It is expected that the association of photobiostimulation techniques with low light; power, using LEDs in the red‐infrared light band and conventional treatment of respiratory physiotherapy are effective in improving lung function, ventilatory mechanics and inspiratory and expiratory muscle strength for the treatment of patients with sars‐cov‐2, in addition to optimizing the clinical condition of the patient with repercussions on respiratory rate and pulse oximetry. SECONDARY OUTCOME: With the use of the photobiomodulation technique associated with respiratory physiotherapy, he hopes to find a decrease in hospital costs and mortality rates. INCLUSION CRITERIA: The research will include patients: aged between 60 and 80 years; with clinical diagnosis of SARS‐Cov‐2; undergoing medical treatment at Santa Casa de Pindamonhangaba and Itajubá; in invasive mechanical ventilation and in drug treatment.
Epistemonikos ID: 4cbf40bf68ff91ff27adbf30cdd3e9aa10b49ebb
First added on: Dec 12, 2020